Regeneron Pharmaceuticals, Inc.
REGNHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeRegeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company carries a $82.88B market cap, placing it firmly in the large-cap category. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions.
Market Cap
$82.88B
Beta
0.15
P/E (TTM)
19.91
P/E (Fwd)
12.84
EPS (TTM)
$40.44
EPS (Fwd)
$62.70
ROE
14.0%
ROA
6.5%
Cash
$7.99B
Total Debt
$2.71B
Free CF
$3.07B
52W Change
37.5%
Annual Financials
Cash vs Debt
Where REGN stands vs its 150-day and 200-day moving averages
As of the October 19, 2026 close, REGN finished 9.37% above its 150-day moving average ($722.98) and 7.72% above its 200-day moving average ($734.06). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is REGN overbought or oversold?
At the October 19, 2026 close, REGN's RSI(14) was 63.5, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $7.99B in cash and $2.71B in debt, REGN maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company generates $3.07B in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 14.0%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 6.5% suggests reasonable efficiency in deploying the company's asset base. Revenue has been uneven over recent years, ranging from $12.17B to $14.34B.
REGN's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. With cash comfortably exceeding debt, REGN has financial flexibility that may help navigate uncertain periods. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Regeneron Pharmaceuticals, Inc.'s trajectory.